The Australian Financial Review reported UPcare's satisfactory breakthrough against SARS-COV-2
The Australian Financial Review rencently reported that UPcare Group is raising $US50 million to support human trials of its botanic compounds , which preclinical studies indicate inhibits SARS-COV-2 virus.
This significant research breakthrough also reported by other Australian mainstream media, such as The Retail Pharmacy Magazine and The Aesthetic Medical Practitioner Magazine.
UPcare Group have been identified by the Doherty Institute that one of its natural compounds UP-A can successfully inhibit SARS-COV-2 infection in Vero cells. Similar levels of inhibition when combined with UPcare's other compounds UP-U and UP-P.
UPcare Group also have been invited to present this satisfactory findings to the White House late last year, said by Monash University professor Zhicheng Xiao. He also had a good constructive discussion about the products with a group of people from the FDA and Centres for Disease Control, which gave him plenty of confidence.
“If its human trials were successful, the company’s therapy and products would receive emergency authorisation by the US Food and Drug Administration.”
It was widely anticipated that Sars-CoV-2 will be around for years. Viruses evolve usually into less deadlier forms. This time humanity faces a microscopic threat that has done the opposite. It is evolving to spread faster, infecting more people and claiming more lives. The public will have to coexist with Covid-19 much as it does with other endemic diseases like flu. Covid will remain persistently present, but the aim is to make it manageable. Society will need to adapt and should expect to have periodic vaccine shot, mask wearing, social distancing and use of anti-bacterial and antiviral products.
Currently, UPcare Group already has successfully got two products approved by TGA, which are UPplus KBD Spray and UPplus A Capsules as complimentary medicines that can boost immunity and inhibit respiratory infection. UPplus KBD Spray is already available in the market while UPplus A Capusles will be ready at the end of Feb 2021.
Source:
For more details about research, human trial investment and distribution cooperation, please feel free to contact: enquiries@upcare.tech
Kommentare